Detalhe da pesquisa
1.
Validation of the UK myeloma research alliance risk profile, a new clinical prediction model for outcome in patients with newly diagnosed multiple myeloma not eligible for autologous stem cell transplantation; a population-based study from the Danish national multiple myeloma registry.
Br J Haematol
; 193(1): 119-124, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32515050
2.
Prognostic significance of infectious episodes occurring during first-line therapy for diffuse large B-cell lymphoma - A nationwide cohort study.
Hematol Oncol
; 38(3): 318-325, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32239673
3.
Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.
Eur J Haematol
; 93(5): 407-13, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24809596
4.
First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.
Eur J Haematol
; 85(4): 290-9, 2010 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-20528908
5.
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database.
Am J Hematol
; 90(4): E73-4, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25561348
6.
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
PLoS One
; 12(12): e0188988, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29216227